86 related articles for article (PubMed ID: 7613556)
1. Dose response studies. I. Some design considerations.
Ruberg SJ
J Biopharm Stat; 1995 Mar; 5(1):1-14. PubMed ID: 7613556
[TBL] [Abstract][Full Text] [Related]
2. Dose response studies. II. Analysis and interpretation.
Ruberg SJ
J Biopharm Stat; 1995 Mar; 5(1):15-42. PubMed ID: 7613559
[TBL] [Abstract][Full Text] [Related]
3. Factorial dose-response studies using frequency and magnitude of dose.
Hafner KB; Ruberg SJ
J Biopharm Stat; 1996 Jul; 6(3):253-62. PubMed ID: 8854230
[TBL] [Abstract][Full Text] [Related]
4. Identifying the maximum safe dose: a multiple testing approach.
Hothorn LA; Hauschke D
J Biopharm Stat; 2000 Feb; 10(1):15-30. PubMed ID: 10709798
[TBL] [Abstract][Full Text] [Related]
5. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
6. Using the partitioning principle to adaptively design dose-response studies.
Ling X; Hsu J
J Biopharm Stat; 2006; 16(5):733-43. PubMed ID: 17037268
[TBL] [Abstract][Full Text] [Related]
7. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
Pritchett YL; Tamura R
Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
[TBL] [Abstract][Full Text] [Related]
8. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
9. Analysis and design of repeated measures in clinical trials using summary statistics.
Ogenstad S
J Biopharm Stat; 1997 Nov; 7(4):593-604. PubMed ID: 9358331
[No Abstract] [Full Text] [Related]
10. An improved method of evaluating drug effect in a multiple dose clinical trial.
Shen L
Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials.
Lledó-García R; Hennig S; Karlsson MO
Clin Pharmacol Ther; 2009 Jul; 86(1):62-9. PubMed ID: 19339964
[TBL] [Abstract][Full Text] [Related]
12. Multiple comparisons and multiple contrasts in randomized dose-response trials--confidence interval oriented approaches.
Hothorn LA
J Biopharm Stat; 2006; 16(5):711-31. PubMed ID: 17037267
[TBL] [Abstract][Full Text] [Related]
13. How to deal with multiple treatment or dose groups in randomized clinical trials?
Hothorn LA
Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
[TBL] [Abstract][Full Text] [Related]
14. Sample sizes for clinical trials with normal data.
Julious SA
Stat Med; 2004 Jun; 23(12):1921-86. PubMed ID: 15195324
[TBL] [Abstract][Full Text] [Related]
15. A multiple comparison procedure to control the strong stagewise family error rate in comparing test treatments and a control.
Chen M; Kianifard F
J Biopharm Stat; 1997 Jul; 7(3):355-67. PubMed ID: 9252830
[TBL] [Abstract][Full Text] [Related]
16. Diet and cancer: the disconnect between epidemiology and randomized clinical trials.
Meyskens FL; Szabo E
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1366-9. PubMed ID: 15941942
[TBL] [Abstract][Full Text] [Related]
17. Analyzing randomized dose finding studies with a primary and a secondary endpoint.
Hothorn LA; Wassmer G
J Biopharm Stat; 2003 May; 13(2):301-5. PubMed ID: 12729396
[TBL] [Abstract][Full Text] [Related]
18. Multivariate estimation of the relative dose potency.
Källén A
Stat Med; 2004 Jul; 23(14):2187-93. PubMed ID: 15236424
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the enoximone clinical trials program.
Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
[TBL] [Abstract][Full Text] [Related]
20. [Ethical problems in randomized clinical trials from the aspect of statistics. Part I. Is patient randomization acceptable from the ethical viewpoint?].
Haas T
Cas Lek Cesk; 2001 Jun; 140(11):335-42. PubMed ID: 11431853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
